4//SEC Filing
ABEL STAN E 4
Accession 0001209191-19-028151
CIK 0001054274other
Filed
May 6, 8:00 PM ET
Accepted
May 7, 9:10 PM ET
Size
11.1 KB
Accession
0001209191-19-028151
Insider Transaction Report
Form 4
ABEL STAN E
Director
Transactions
- Award
Common Stock
2019-05-03+54,117→ 54,117 total - Award
Stock Option (Right to Buy)
2019-05-03+198→ 198 totalExercise: $1.39Exp: 2022-12-17→ Common Stock (198 underlying) - Award
Stock Option (Right to Buy)
2019-05-03+27,940→ 27,940 totalExercise: $3.06Exp: 2026-12-15→ Common Stock (27,940 underlying)
Footnotes (3)
- [F1]Shares of common stock of the corporation then known as Adynxx, Inc. ("Private Adynxx") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, by and among the Issuer, Embark Merger Sub, Inc. and Private Adynxx (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.0359 shares of the Issuer's common stock. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of common stock outstanding.
- [F2]On December 18, 2012, Reporting Person was granted an option to purchase 5,520 shares of the common stock of Private Adynxx under Private Adynxx's Equity Incentive Plan at an exercise price of $0.05 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 198 shares of the Issuer's common stock at a per share exercise price of $1.39. This option is fully vested.
- [F3]On December 16, 2016, Reporting Person was granted an option to purchase 778,264 shares of the common stock of Old Adynxx under Old Adynxx's Equity Incentive Plan at an exercise price of $0.11 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 27,940 shares of the Issuer's common stock at a per share exercise price of $3.06. Subject to Reporting Person's continued employment, 1/4th of the option vested and became exercisable on December 16, 2017 with the remainder vesting monthly thereafter for a total vesting period of 48 months. Upon a change of control of the Issuer, 100% of any unvested portion of the option will become fully vested and exercisable.
Documents
Issuer
Alliqua BioMedical, Inc.
CIK 0001054274
Entity typeother
Related Parties
1- filerCIK 0001281717
Filing Metadata
- Form type
- 4
- Filed
- May 6, 8:00 PM ET
- Accepted
- May 7, 9:10 PM ET
- Size
- 11.1 KB